Preserving Muscle on a GLP-1: The Complete 2026 Playbook

Weight loss can include both fat and lean tissue. Lean tissue is not identical to skeletal muscle. Nutrition and physical activity deserve attention during treatment.

A 2026 study in Cell Reports Medicine looked at body composition during GLP-1 weight loss in both mice and humans. It found that weight loss with these medicines does not produce a disproportionate loss of muscle. Yes, absolute muscle mass dips. But relative to body size, muscle quality and function held up, and in the animal models running performance actually improved.

Protein needs during weight loss should be individualized with a clinician or dietitian, particularly when kidney disease or other nutritional concerns are present.

This is the real problem on a GLP-1. The drug works by quieting hunger, which is great for fat loss and terrible for forcing down a chicken breast. So you change tactics. You prioritize protein first at every meal, before the carbs and fats fill you up.

Simple and boring beats fancy and skipped. Two to three sessions a week. Cover the big movements: a push (push-ups, a press), a pull (rows), a squat or sit-to-stand, and a hinge (hip hinge, glute bridge). Two or three sets each. Stop a rep or two before failure. That is a complete starter program.

On a GLP-1 your energy can dip, especially early. So scale to how you feel. A short session you actually do beats a brutal one you dread and cancel. The resistance training on a GLP-1 guide walks through a full beginner block, including how to train when energy is low.

A 2026 study in Cell Reports Medicine examined GLP-1 weight loss in obese mice and humans. It found the medicines predominantly reduce fat, with a smaller drop in lean mass, and that loss of liver mass exceeded change in muscle. Absolute muscle dipped, but relative muscle quality and function improved. The "muscle scare" was overstated ¹.

Compounded medicines are not FDA-approved. Ask the prescriber and dispensing pharmacy why a compounded product is being considered, how it differs from an approved product, and what current requirements apply. A patient-specific prescription does not make a compounded medicine FDA-approved. ⁹.

In ATTAIN-1, adults without diabetes receiving the highest trial dose of orforglipron averaged 12.4% weight loss at 72 weeks under the efficacy estimand, versus 0.9% with placebo. This trial result does not establish muscle preservation. Individual results vary.

The 2026 evidence is reassuring. Studies suggest the loss is not disproportionate and that function tends to hold, especially with protein and training. Older adults and people with low starting muscle should be more deliberate. Talk to your physician about your individual risk ¹.